Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection

被引:17
作者
Axelrad, Jordan E. [1 ]
Li, Terry [2 ]
Bachour, Salam P. [3 ]
Nakamura, Takahiro, I [4 ]
Shah, Ravi [3 ]
Sachs, Michael C. [5 ]
Chang, Shannon [1 ]
Hudesman, David P. [1 ]
Holubar, Stefan D. [6 ]
Lightner, Amy L. [6 ]
Barnes, Edward L. [7 ]
Cohen, Benjamin L. [8 ]
Rieder, Florian [8 ]
Esen, Eren [9 ]
Remzi, Feza [9 ]
Regueiro, Miguel [8 ]
Click, Benjamin [8 ]
机构
[1] NYU, Dept Med, Divison Gastroenterol, Grossman Sch Med, New York, NY 10016 USA
[2] NYU, Dept Med, Grossman Sch Med, New York, NY 10016 USA
[3] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
[4] Univ Vermont, Dept Med, Divison Gastroenterol, Larner Coll Med, Burlington, VT USA
[5] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[6] Cleveland Clin, Dept Colorectal Surg, Cleveland, OH 44106 USA
[7] UNC Sch Med, Dept Med, Div Gastroenterol, Chapel Hill, NC USA
[8] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA
[9] NYU, Dept Surg, Grossman Sch Med, New York, NY 10016 USA
关键词
Crohn's disease; postoperative recurrence; resection; biologic therapy; MAGNETIC-RESONANCE ENTEROGRAPHY; COMPUTED-TOMOGRAPHY; ILEOCOLIC RESECTION; METAANALYSIS; ADALIMUMAB; RISK; PREVENTION; MANAGEMENT;
D O I
10.1093/ibd/izac158
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Lay Summary Postoperative recurrence of Crohn's disease is common after ileocecal resection. In this dual-center study, early initiation of an anti-TNF agent within 4 weeks following an ileocecal resection was associated with a reduction in postoperative recurrence of Crohn's disease. Background Postoperative recurrence (POR) of Crohn's disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR). Methods We performed a retrospective cohort study of CD patients who underwent an ICR at 2 medical centers. Recurrence was defined by endoscopy (>= i2b Rutgeerts score) or radiography (active inflammation in neoterminal ileum) and stratified by type and timing of postoperative prophylactic biologic within 12 weeks following an ICR (none, tumor necrosis factor antagonists [anti-TNF], vedolizumab, and ustekinumab). Results We identified 1037 patients with CD who underwent an ICR. Of 278 (26%) who received postoperative prophylaxis, 80% were placed on an anti-TNF agent (n = 223) followed by ustekinumab (n = 28, 10%) and vedolizumab (n = 27, 10%). Prophylaxis was initiated in 35% within 4 weeks following an ICR and in 65% within 4 to 12 weeks. After adjusting for factors associated with POR, compared with no biologic prophylaxis, the initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR (adjusted hazard ratio, 0.61; 95% CI, 0.40-0.93). Prophylaxis after 4 weeks following an ICR or with vedolizumab or ustekinumab was not associated with a reduction in POR compared with those who did not receive prophylaxis. Conclusion Early initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR. Vedolizumab or ustekinumab, at any time following surgery, was not associated with a reduction in POR, although sample size was limited.
引用
收藏
页码:888 / 897
页数:10
相关论文
共 50 条
  • [21] Impact of Infliximab Therapy After Early Endoscopic Recurrence Following Ileocolonic Resection of Crohn's Disease: A Prospective Pilot Study
    Yamamoto, Takayuki
    Umegae, Satoru
    Matsumoto, Koichi
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (10) : 1460 - 1466
  • [22] Tailored treatment according to early post-surgery colonoscopy reduces clinical recurrence in Crohn's disease: A retrospective study
    Baudry, Clotilde
    Pariente, Benjamin
    Lourenco, Nelson
    Simon, Marion
    Chirica, Mircea
    Cattan, Pierre
    Munoz-Bongrand, Nicolas
    Gornet, Jean-Marc
    Allez, Matthieu
    DIGESTIVE AND LIVER DISEASE, 2014, 46 (10) : 887 - 892
  • [23] Risk factors for postoperative recurrence after primary bowel resection in patients with Crohn's disease
    Yang, Kwan Mo
    Yu, Chang Sik
    Lee, Jong Lyul
    Kim, Chan Wook
    Yoon, Yong Sik
    Park, In Ja
    Lim, Seok-Byung
    Park, Sang Hyoung
    Ye, Byong Duk
    Yang, Suk-Kyun
    Kim, Jin Cheon
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (38) : 7016 - 7024
  • [24] Factors associated with anti-tumor necrosis factor effectiveness to prevent postoperative recurrence in Crohn's disease
    Buisson, Anthony
    Cannon, Lisa
    Umanskiy, Konstantin
    Hurst, Roger D.
    Hyman, Neil H.
    Sakuraba, Atsushi
    Pekow, Joel
    Dalal, Sushila
    Cohen, Russell D.
    Pereira, Bruno
    Rubin, David T.
    INTESTINAL RESEARCH, 2022, 20 (03) : 303 - +
  • [25] Complications and Disease Recurrence After Ileocecal Resection in Pediatric Crohn's Disease: A Retrospective Study
    Glenisson, M.
    Bonnard, A.
    Berrebi, D.
    Belarbi, N.
    Viala, J.
    Martinez-Vinson, C.
    EUROPEAN JOURNAL OF PEDIATRIC SURGERY, 2024, 34 (03) : 253 - 260
  • [26] Anti-Tumor Necrosis Factor Therapy to Prevent Crohn's Disease Recurrence After Surgery
    Herfarth, Hans H.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1503 - 1506
  • [27] Risk Factors for Complications and Disease Recurrence after Ileocecal Resection for Crohn's Disease in Children and Adults
    Dipasquale, Valeria
    Milone, Erica
    Nigro, Stefania
    Alibrandi, Angela
    Antonelli, Enrica
    Di Fabrizio, Donatella
    Romeo, Carmelo
    Navarra, Giuseppe
    Romano, Claudio
    BIOMEDICINES, 2024, 12 (04)
  • [28] Frequency and Risk Factors of Postoperative Recurrence of Crohn's Disease After Intestinal Resection in the Chinese Population
    Li, Yi
    Zhu, Weiming
    Zuo, Lugen
    Zhang, Wei
    Gong, Jianfeng
    Gu, Lili
    Cao, Lei
    Li, Ning
    Li, Jieshou
    JOURNAL OF GASTROINTESTINAL SURGERY, 2012, 16 (08) : 1539 - 1547
  • [29] Inflammatory Cytokine Profile in Crohn's Disease Nonresponders to Optimal Antitumor Necrosis Factor Therapy
    Yarur, Andres J.
    Jain, Anjali
    Quintero, Maria A.
    Czul, Frank
    Deshpande, Amar R.
    Kerman, David H.
    Abreu, Maria T.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2019, 53 (03) : 210 - 215
  • [30] Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn's Disease Recurrence
    Yu, Jongwook
    Hyun, Hye Kyung
    Park, Jihye
    Kang, Eun Ae
    Park, Soo Jung
    Park, Jae Jun
    Kim, Tae Il
    Kim, Won Ho
    Cheon, Jae Hee
    GUT AND LIVER, 2022, 16 (03) : 414 - 422